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Meningococcal septic shock (MSS) is a fulminant form of sepsis
characterized by an overwhelming production of pro- and anti-
inﬂammatory cytokines, together with metabolic derangement.1
Hyperglycemia is associated with a signiﬁcantly worse outcome in
children affected by meningococcal sepsis.2 In critically ill adult
patients in general, and in patients with sepsis in particular,
hyperglycemia and insulin resistance are long universal ﬁndings.3
In contrast, in critically ill children with MSS, hyperglycemia
correlated with hypoinsulinemia rather than insulin resistance has
been described.1
Intensive insulin therapy has already been recommended for
the management of hyperglycemia in severe sepsis and septic
shock in some adult populations, but there is a paucity of data for
the pediatric intensive care setting.1,3 Evidence is growing that
strictly maintaining normoglycemia improves the outcome in
critical illness, decreasing both morbidity and mortality.2,3
However the risk of hypoglycemia has raised concerns about
insulin supplementation, even if its clinical relevance remains to be
deﬁned.1,3 Whether intensive insulin therapy per se or lowered
glucose levels by intensive insulin therapy is the main mechanism
in the beneﬁcial effect of tight glycemic control has yet to be
determined.2,3It has recently been reported that anti-inﬂammato-
ry effects of insulin may contribute to the protective beneﬁts
against organ injury/dysfunction caused by extensive systemic
inﬂammation, independently of any effect on blood glucose.3,4
Insulin has been shown to reduce the catabolic response, as well as
to control hyperglycemia and limit apoptosis damage.3,4 It seems
to have the ability to suppress the production of proinﬂammatory
cytokines and acute phase proteins with a direct effect on the
transcriptional nuclear factor-kappa B (NF-kB) that modulates the
proinﬂammatory cytokines, adhesion molecules and chemo-
kines.4–6 Insulin has been described to suppress the production
of tumor necrosis factor-alpha (TNF-a), interleukin-1 (IL-1),
interleukin-6 (IL-6), macrophage migration inhibitory factor
(MIF), and reactive oxygen species (ROS).5,6 In addition, this
hormone has been described to increase the production of anti-
inﬂammatory cytokines interleukin-4 (IL-4) and interleukin-10
(IL-10) and the synthesis of endothelial nitric oxide (eNO).4–61201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.03.012With respect to the above, we hypothesize that children
suffering from MSS with insulin deﬁciency may derive clinical
beneﬁts from insulin replacement, because this approach may be
considered as supplementing a deﬁcient vital hormone. Insulin
may be lifesaving by suppressing systemic inﬂammation indepen-
dently of controlling hyperglycemia. Randomized controlled trials
are needed in order to introduce intensive insulin therapy into the
treatment guidelines for this group of patients.
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